SANTA CLARA, Calif.,SEATTLE, Wash., Jan. 10, 2012

Agilent Technologies Inc. (NYSE: A)Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.

Integrated Diagnostics, an emerging leader in molecular diagnostics, is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomicsgenomics to detect diseases such as lung cancerAlzheimer's at their earliest stages. Agilent manufactures a wide range of analytical instrumentation, including liquid chromatography, mass spectrometryautomation systems. Officials of both organizations see an opportunity to rapidly turn medical breakthroughs into diagnostic assays by combining efforts to focus on proteinpeptide biomarkers of disease.

"Agilent provides an innovativeforward-looking platformexpertise to enable the developmentdeployment of next-generation multiplexed proteomic assays," said Paul Kearney, Ph.D., presidentchief scientific officer, Integrated Diagnostics. "Integrated Diagnostics will bring expertise in assay development, technology strategy, study design, clinical development, commercializationsystems informatics to leverage the Agilent technology solution. Together, we intend to realize the potential of clinical proteomics today as well as establish the technological platformstrategy for the field. Our partnership with Agilent will allow us to realize the advantages of using a single technology platform from discoveryverification through to commercialization."

"AgilentIntegrated Diagnostics share the vision of harnessing the power of an integrative systems biology approach to solving some of mankind's most vexing health challenges," said Gustavo Salem, vice presidentgeneral manager of the Biological Systems Division at Agilent. "It's very exciting to be at the forefront of helping technology migrate from the research lab to the clinic, in this case developing next-generation workflows to improve protein-based LC/MS assays."

As part of the partnership, Integrated Diagnostics purchased two Agilent 1290 Infinity UHPLC systems, two 6490 iFunnel triple quadrupole mass spectrometry systemstwo 1260 LCs with ultraviolet detectors for the project.

The partnership will develop high-throughput automated workflows to include sample preparationLC MS/MS analysis. Participants expect accelerated biomarker discovery to be fueled by novel sample-prep technology, fast liquid chromatographyultra-sensitive ion funnel triple quadrupole mass spectrometry.

The technology opens the possibility of screening for several hundred biomarkers in a single assay, in a very high-throughputquantitative fashion, according to Agilent.

About Integrated Diagnostics

at their earliest stages by simultaneously monitoring tens to hundreds of disease markers. The company, founded in October 2009 by systems biology pioneer /press-releases/molecular-diagnostics/executive-team-founders/lee-hood/>Dr. Lee Hood, is creating a new generation of personalized medical solutions using sophisticated informatics for a novel class of synthetically created diagnostictherapeutic agents with antibody-like properties: . Integrated Diagnostics' mission is to build a new generation of low-cost, large-scale diagnostic assays for early detection of serious diseases. The company is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes,other molecules. Investors include InterWest Partners, The Wellcome Trust,BioTechCube Luxembourg. Foundational intellectual property is exclusively licensed from the Institute of Systems BiologyCaltech. Learn more at .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement companya technology leader in chemical analysis, life sciences, electronicscommunications. The company's 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at .

# # #

Contact:

Stuart Matlow, Agilent
+1 408 553 7191
stuart_matlow@agilent.com

Eliot Dobris, for Integrated Diagnostics
+1 415 902 1241
eliot@eliotdobris.com


distribué par

Ce noodl a été diffusé par Agilent Technologies Inc. et initialement mise en ligne sur le site http://www.agilent.com. La version originale est disponible ici.

Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-10 17:21:28 PM et restera accessible depuis ce lien permanent.

Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.